AI Scribes vs Human Scribes in Ophthalmology: An Honest Comparison

Full disclosure before a word of comparison: we provide human virtual scribes, so we have a horse in this race. We're writing the comparison anyway because the question deserves a straight answer, and because the straight answer is more interesting than either sales pitch — AI scribes are genuinely good at some things, human scribes at others, and the practices making the smartest choices understand which is which.

What AI scribes do well

Modern ambient AI documentation tools listen to the visit and generate a draft note, and for conversation-heavy encounters they've become impressively capable. Their strengths are real: they're always available, they scale to every room at once, they never call in sick, and their per-encounter cost undercuts any human arrangement. For narrative-driven specialties — primary care visits that are mostly dialogue — they capture the substance of the encounter well and keep improving.

They also never get bored. The fortieth encounter of the day is transcribed with the same fidelity as the first, which is more than can be guaranteed of any human.

Where ophthalmology breaks them

Eye care is close to a worst case for audio-only documentation, for a structural reason: much of the exam's content is never spoken. The slit-lamp findings you observe but don't fully narrate, the OCT you interpret on a second screen, the IOP the tech recorded an hour ago, the visual field you compare against last year's — an ambient tool hears none of it. What it hears is a partial soundtrack of a visual encounter, and it drafts accordingly. Doctors using ambient AI in eye clinics report the same pattern: usable history sections, thin exam sections, and plans that need rebuilding whenever the decision rested on imaging.

Add the vocabulary problem — ophthalmic terminology, drug names, and abbreviations that speech recognition renders creatively — and the "review and correct" step can consume a large share of the time the tool promised to save. A note that's 85% right isn't 85% of the value; the doctor still has to find the 15%.

A human scribe working in your EHR doesn't share these limits. They see the imaging orders, pull forward the tech's workup, know your template, and ask when something's unclear — the one capability no ambient tool has.

Where human scribes lose

Fairness requires this list too. Human scribes cost more per hour than software by a wide margin. They cover one doctor at a time, not a whole clinic. They need onboarding measured in weeks, vacation coverage, and management attention. A poorly trained scribe is worse than software, because bad structured documentation looks trustworthy. And the supply of scribes who genuinely know eye care is limited — which is much of why virtual staffing exists at all.

The hybrid pattern emerging

The most sophisticated practices we see aren't choosing sides. A typical division: ambient AI drafts the routine, conversation-heavy encounters; a human scribe (often virtual) owns medical and surgical documentation where imaging, structured findings, and coding stakes dominate; and the human also does what AI can't — tees up orders, drafts referral letters, keeps the chart moving between visits. The economics work because each tool covers the encounters it's actually good at.

How to decide for your practice

Three questions get you most of the way:

• What share of your documentation pain is exam-and-imaging-driven versus conversation-driven? Heavily medical and surgical practices tilt human; routine-heavy practices can extract real value from AI drafts.
• Who reviews and how carefully? If your doctors will honestly proof every AI note, the correction burden is manageable. If they'll sign drafts on autopilot by week three — most will — structured human documentation is safer.
• What's your coding exposure? Notes supporting medical necessity for injections, imaging, and surgery face payer scrutiny. Documentation built by someone who understands what the note must support is a form of insurance.

Try the AI tools; trials are cheap and the technology is moving. But measure the after-review time savings, not the demo. And if the review burden lands where most eye clinics find it, you'll understand why the human version of this role — increasingly virtual, for reach and cost — is still growing right alongside the software that was supposed to replace it.